At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
PX-866drug
Likely dose
PX-866 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating PX-866 for Prostate Cancer. Completed, enrolled 68 participants across 10 sites.
Detailed Summary
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your prostate cancer. The investigators will also watch you carefully for any side effects that PX-866 might cause.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesCanada
CollaboratorsOncothyreon Canada Inc.
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2011
Enrollment StartSep 2011
Primary CompletionJan 2015
Study CompletionNov 2015
TodayJul 2026
First PostedApr 7, 2011
Enrollment StartSep 9, 2011
Primary CompletionJan 13, 2015
Study CompletionNov 27, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.2 years ago
Interventions
PX-866drug
PX-866: 8mg orally taken daily